SEA-TGT for Cancer
Trial Summary
What is the purpose of this trial?
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Eligibility Criteria
This trial is for adults with certain advanced cancers (like lung, stomach, skin, breast cancer) or lymphomas that can't be removed by surgery. Participants should have a good performance status and measurable disease. They can't join if they've used certain treatments recently, have brain metastases, autoimmune diseases, a history of another cancer within 2 years (with some exceptions), or specific lung conditions.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Brentuximab Vedotin (Monoclonal Antibodies)
- Sasanlimab (Monoclonal Antibodies)
- SEA-TGT (Monoclonal Antibodies)